1
|
Abstract
Over the last decade, the “traditional” drug scene has been supplemented – but not replaced – by the emergence of a range of novel psychoactive substances (NPS), which are either newly created or existing drugs, including medications, now being used in novel ways. By the end of 2015, in excess of 700 NPS had been reported by a large number of countries in the world. Most recent data show however that synthetic cathinones; synthetic cannabinoids; and psychedelics/phenethylamines; account for the largest number of NPS. Given the vast range of medical and psychopathological issues associated with the molecules here described, it is crucial for health professionals to be aware of the effects and toxicity of NPS. The “Drugs 2.0.” revolution facilitated the birth and growth of an “Online Drug Culture” which finds its main expression in chats/fora/blogs as well as the diffusion of online drug marketplaces (both in the surface and deep web). The web has progressively modified the drug market from a “street” into a “virtual” one, so by increasing the availability of new drugs/NPS/“legal highs” (“legal alternatives” to the traditional illegal drugs). The rapid pace of change in the NPS online market constitutes a major challenge to the provision of current and reliable scientific knowledge on these substances. The present lecture aims at providing an overview of the NPS phenomenon, also giving an overview of the main clinical and pharmacological issues relating to these most popular NPS categories.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
2
|
Fornaro M, Iasevoli F, Novello S, Fusco A, Anastasia A, De Berardis D, Valchera A, de Bartolomeis A. Predictors of hospitalization length of stay among re-admitted treatment-resistant Bipolar Disorder inpatients. J Affect Disord 2018; 228:118-124. [PMID: 29245092 DOI: 10.1016/j.jad.2017.12.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Revised: 11/08/2017] [Accepted: 12/05/2017] [Indexed: 02/04/2023]
Abstract
BACKGROUND Hospitalization accounts for significant health care resource utilization for treatment-resistant Bipolar Disorder (BD), especially among frequent users of acute inpatient psychiatric units. Appraisal of the clinical features and predictive role of selected variables is therefore crucial in such population, representing the aim of the present research. METHODS A hundred and nineteen BD inpatients with an established history of pharmacological treatment resistance for either mania or bipolar depression were classified as long hospitalization cases (LOS+) and their controls and compared against each other for a number of demographic, clinical, and psychopathological features. RESULTS Overall, female sex, current second-generation atypical antipsychotic (SGA)/mood stabilizer other than lithium as well as antidepressant treatment at the admission occurred statistically more frequently among LOS+ cases, concordant with higher scores at the Hamilton scales for depression and anxiety. Lithium utilization at the time of hospitalization did not differ between cases and controls (LOS-, n = 81/119), as predominant affective temperament and other psychopathological rating did not. Overall, the time of admission, use of SGA, anticonvulsant (other than lithium), antidepressant, lifetime alcohol dependence, and BD Type (-I or -II), but not current mood polarity at the time of hospitalization, correctly predicted LOS+ grouping 68.2% of the times: Exp(B) = 3.151, p042. LIMITATIONS Post-hoc, cross-sectional study, relatively small sample size, recall and selection bias on some diagnoses. CONCLUSIONS Overall, LOS+ treatment-resistant BD inpatients characterize for higher severity and greater pharmaco-utilization use, which warrants replication studies to include additional predictors to shed further light on the matter.
Collapse
Affiliation(s)
- M Fornaro
- Unit on Treatment Resistant Disorders, Department of Neuroscience, Reproductive Sciences and Odontostomatology University School of Medicine Federico II, Naples, Via Pansini 5, 80131 Napoli, Italy.
| | - F Iasevoli
- Unit on Treatment Resistant Disorders, Department of Neuroscience, Reproductive Sciences and Odontostomatology University School of Medicine Federico II, Naples, Via Pansini 5, 80131 Napoli, Italy.
| | - S Novello
- Unit on Treatment Resistant Disorders, Department of Neuroscience, Reproductive Sciences and Odontostomatology University School of Medicine Federico II, Naples, Via Pansini 5, 80131 Napoli, Italy.
| | - A Fusco
- Unit on Treatment Resistant Disorders, Department of Neuroscience, Reproductive Sciences and Odontostomatology University School of Medicine Federico II, Naples, Via Pansini 5, 80131 Napoli, Italy.
| | - A Anastasia
- Unit on Treatment Resistant Disorders, Department of Neuroscience, Reproductive Sciences and Odontostomatology University School of Medicine Federico II, Naples, Via Pansini 5, 80131 Napoli, Italy.
| | - D De Berardis
- NHS, Department of Mental Health ASL Teramo, Psychiatric Service of Diagnosis and Treatment, Hospital 'G. Mazzini', Teramo, Italy.
| | - A Valchera
- Villa San Giuseppe Hospital, Hermanas Hospitalarias, Ascoli Piceno, Italy.
| | - A de Bartolomeis
- Unit on Treatment Resistant Disorders, Department of Neuroscience, Reproductive Sciences and Odontostomatology University School of Medicine Federico II, Naples, Via Pansini 5, 80131 Napoli, Italy.
| |
Collapse
|
3
|
De Berardis D, Mazza M, Marini S, Del Nibletto L, Serroni N, Pino MC, Valchera A, Ortolani C, Ciarrocchi F, Martinotti G, Di Giannantonio M. Psychopathology, emotional aspects and psychological counselling in infertility: a review. Clin Ter 2016; 165:163-9. [PMID: 24999571 DOI: 10.7417/ct.2014.1716] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Over the years, infertility has been variably defined. Infertility affects approximately 80 million people from all parts of the world. An important area of discussion has been represented by the possible causal link between psychopathology and infertility. In the past, the prevalence of psychiatric problems among infertile couples was estimated to be 25-60%. The incidence of depression and anxiety in infertile couples is significantly high than in fertile controls and in the general population respectively. Infertility has been linked to obsessive-compulsive symptoms, psychoticism, substance abuse and eating disorders. Psychological impact of infertility is greater in women than in men. Additionally, authors found that infertile patients were more alexithymic than healthy controls. In relation to the different needs, different psychological therapeutic interventions may be indicated. Psychological counseling can provide valuable assistance in dealing with infertility treatments and their eventual failures.
Collapse
Affiliation(s)
- D De Berardis
- NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital "G. Mazzini", ASL 4 Teramo - Department of Neurosciences and Imaging, Chair of Psychiatry, University "G. D'Annunzio", Chieti
| | - M Mazza
- Department of Life, Health and Environmental Sciences, University of L'Aquila
| | - S Marini
- NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital "G. Mazzini", ASL 4 Teramo - Department of Neurosciences and Imaging, Chair of Psychiatry, University "G. D'Annunzio", Chieti
| | - L Del Nibletto
- NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital "G. Mazzini", ASL 4 Teramo
| | - N Serroni
- NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital "G. Mazzini", ASL 4 Teramo
| | - M C Pino
- Department of Life, Health and Environmental Sciences, University of L'Aquila
| | - A Valchera
- Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, Ascoli Piceno
| | - C Ortolani
- Department of "Scienze della Formazione", University of Teramo
| | - F Ciarrocchi
- U.O.C. Obstetrics and Gynecology, ASL 4 Teramo, Italy
| | - G Martinotti
- Department of Neurosciences and Imaging, Chair of Psychiatry, University "G. D'Annunzio", Chieti
| | - M Di Giannantonio
- Department of Neurosciences and Imaging, Chair of Psychiatry, University "G. D'Annunzio", Chieti
| |
Collapse
|
4
|
Orsolini L, Tomasetti C, Valchera A, Vecchiotti R, Matarazzo I, Vellante F, Iasevoli F, Buonaguro EF, Fornaro M, Fiengo ALC, Martinotti G, Mazza M, Perna G, Carano A, De Bartolomeis A, Di Giannantonio M, De Berardis D. An update of safety of clinically used atypical antipsychotics. Expert Opin Drug Saf 2016; 15:1329-47. [PMID: 27347638 DOI: 10.1080/14740338.2016.1201475] [Citation(s) in RCA: 71] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
INTRODUCTION The atypical antipsychotic (APs) drugs have become the most widely used agents to treat a variety of psychoses because of their superiority with regard to safety and tolerability profile compared to conventional/'typical' APs. AREAS COVERED We aimed at providing a synthesis of most current evidence about the safety and tolerability profile of the most clinically used atypical APs so far marketed. Qualitative synthesis followed an electronic search made inquiring of the following databases: MEDLINE, Embase, PsycINFO and the Cochrane Library from inception until January 2016, combining free terms and MESH headings for the topics of psychiatric disorders and all atypical APs as following: ((safety OR adverse events OR side effects) AND (aripiprazole OR asenapine OR quetiapine OR olanzapine OR risperidone OR paliperidone OR ziprasidone OR lurasidone OR clozapine OR amisulpride OR iloperidone)). EXPERT OPINION A critical issue in the treatment with atypical APs is represented by their metabolic side effect profile (e.g. weight gain, lipid and glycaemic imbalance, risk of diabetes mellitus and diabetic ketoacidosis) which may limit their use in particular clinical samples. Electrolyte imbalance, ECG abnormalities and cardiovascular adverse effects may recommend a careful baseline and periodic assessments.
Collapse
Affiliation(s)
- L Orsolini
- a School of Life and Medical Sciences , University of Hertfordshire , Hatfield , Herts , United Kingdom.,b Villa San Giuseppe Hospital, Hermanas Hospitalarias , Ascoli Piceno , Italy.,c Polyedra Research Group , Teramo , Italy.,d Department of Psychiatry and Neuropsychology , University of Maastricht , Maastricht , The Netherlands
| | - C Tomasetti
- c Polyedra Research Group , Teramo , Italy.,e NHS, Department of Mental Health ASL Teramo , Psychiatric Service of Diagnosis and Treatment, Hospital 'Maria SS dello Splendore,' Giulianova , Italy.,f Laboratory of Molecular and Translational Psychiatry, Department of Neuroscience, Reproductive and Odontostomatogical Sciences , University of Naples 'Federico II,' Napoli , Italy
| | - A Valchera
- b Villa San Giuseppe Hospital, Hermanas Hospitalarias , Ascoli Piceno , Italy.,c Polyedra Research Group , Teramo , Italy
| | - R Vecchiotti
- b Villa San Giuseppe Hospital, Hermanas Hospitalarias , Ascoli Piceno , Italy.,c Polyedra Research Group , Teramo , Italy.,d Department of Psychiatry and Neuropsychology , University of Maastricht , Maastricht , The Netherlands
| | - I Matarazzo
- g NHS, Department of Mental Health ASL Teramo, Psychiatric Service of Diagnosis and Treatment , Hospital 'G. Mazzini,' Teramo , Italy.,h Department of Neuroscience and Imaging , University 'G. D'Annunzio,' Chieti , Italy
| | - F Vellante
- g NHS, Department of Mental Health ASL Teramo, Psychiatric Service of Diagnosis and Treatment , Hospital 'G. Mazzini,' Teramo , Italy.,h Department of Neuroscience and Imaging , University 'G. D'Annunzio,' Chieti , Italy
| | - F Iasevoli
- c Polyedra Research Group , Teramo , Italy.,f Laboratory of Molecular and Translational Psychiatry, Department of Neuroscience, Reproductive and Odontostomatogical Sciences , University of Naples 'Federico II,' Napoli , Italy
| | - E F Buonaguro
- c Polyedra Research Group , Teramo , Italy.,f Laboratory of Molecular and Translational Psychiatry, Department of Neuroscience, Reproductive and Odontostomatogical Sciences , University of Naples 'Federico II,' Napoli , Italy
| | - M Fornaro
- c Polyedra Research Group , Teramo , Italy.,i New York Psychiatric Institute , Columbia University , New York , NY , USA
| | | | - G Martinotti
- h Department of Neuroscience and Imaging , University 'G. D'Annunzio,' Chieti , Italy
| | - M Mazza
- c Polyedra Research Group , Teramo , Italy.,j Department of Life, Health and Environmental Sciences , University of L'Aquila , L'Aquila , Italy
| | - G Perna
- k Department of Clinical Neurosciences , Hermanas Hospitalarias, FoRiPsi, Villa San Benedetto Menni, Albese con Cassano , Como , Italy.,l Department of Psychiatry and Behavioral Sciences, Leonard Miller School of Medicine , University of Miami , Miami , FL , USA
| | - A Carano
- m NHS, Department of Mental Health ASL Ascoli Piceno, Psychiatric Service of Diagnosis and Treatment , Hospital 'Maria SS del Soccorso,' San Benedetto del Tronto , Italy
| | - A De Bartolomeis
- f Laboratory of Molecular and Translational Psychiatry, Department of Neuroscience, Reproductive and Odontostomatogical Sciences , University of Naples 'Federico II,' Napoli , Italy
| | - M Di Giannantonio
- i New York Psychiatric Institute , Columbia University , New York , NY , USA
| | - D De Berardis
- c Polyedra Research Group , Teramo , Italy.,g NHS, Department of Mental Health ASL Teramo, Psychiatric Service of Diagnosis and Treatment , Hospital 'G. Mazzini,' Teramo , Italy.,h Department of Neuroscience and Imaging , University 'G. D'Annunzio,' Chieti , Italy
| |
Collapse
|
5
|
Gambi F, De Berardis D, Campanella D, Carano A, Sepede G, Salini G, Scorrano B, Spinella S, Conti C, La Rovere R, Valchera A, Mancini E, Ceddia D, Marchionni L, Calcagni E, Cotellessa C, Salerno R, Ferro F. A Retrospective Evaluation of the Inflammatory Marker C-Reactive Protein (CRP), Cholesterol and High-Density Lipoproteins in Patients with Major Depression: Preliminary Findings. EUR J INFLAMM 2016. [DOI: 10.1177/1721727x0500300304] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
The aim of this study was to retrospectively evaluate the role of C-reactive protein, total cholesterol and high-density lipoprotein cholesterol in patients suffering from Major Depression (MD). Data of C-reactive protein, total cholesterol (TC) and high-density lipoprotein cholesterol of 37 adult outpatients (17 men, 20 women) with a DSM-IV diagnosis of MD were analyzed. Depression was measured with the 17-item Hamilton Depression Rating Scale (HAM-D) and with the Beck Depression Inventory (BDI). Suicide risk was evaluated with the Scale of Suicide Ideation (SSI). Patients with a lifetime history of attempted suicide were categorized as having higher suicide risk. Higher suicide risk patients showed higher C-reactive protein levels and lower high-density lipoprotein cholesterol levels than lower suicide risk patients whereas total cholesterol levels were not statistically different. C-reactive protein positively correlated with BDI, HAM-D, SSI scores and with number of previous depressive episodes. High-density lipoprotein cholesterol correlated inversely with BDI, HAM-D and SSI scores, whereas, no significant correlations were found between Total Cholesterol and other variables including C-reactive protein. In linear regression models, C-reactive protein was predictor of more severe depression and increased suicide risk. Lower high-density lipoprotein cholesterol levels were significantly predictive of increased suicide risk.
Collapse
Affiliation(s)
- F. Gambi
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. D'Annunzio” of Chieti
| | - D. De Berardis
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. D'Annunzio” of Chieti
- ASUR Marche 8
- Marinferm, Italian Navy, Ancona
| | - D. Campanella
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. D'Annunzio” of Chieti
| | - A. Carano
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. D'Annunzio” of Chieti
| | - G. Sepede
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. D'Annunzio” of Chieti
| | - G. Salini
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. D'Annunzio” of Chieti
| | - B. Scorrano
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. D'Annunzio” of Chieti
| | - S. Spinella
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. D'Annunzio” of Chieti
| | - C.M. Conti
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. D'Annunzio” of Chieti
| | - R. La Rovere
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. D'Annunzio” of Chieti
| | | | - E. Mancini
- Marinferm, Italian Navy, Ancona
- Chinical Psychology, University of Chieti
| | | | | | | | - C. Cotellessa
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. D'Annunzio” of Chieti
| | - R.M. Salerno
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. D'Annunzio” of Chieti
| | - F.M. Ferro
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. D'Annunzio” of Chieti
| |
Collapse
|
6
|
Orsolini L, Papanti D, Valchera A, Vecchiotti R, Corkery J, Schifano F. Is addiction medicine part of psychiatry? Eur Psychiatry 2016. [DOI: 10.1016/j.eurpsy.2016.01.810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Addiction medicine/psychiatry, a medical subspecialty founded on October 1991 by the American Board of Psychiatry and Neurology, was granted as subspecialty within psychiatry. It mainly deals with medical assessment, diagnosis and treatment of subjects who suffer from an addiction (i.e. drug and/or alcohol addiction; gambling; sexual addiction; game addiction; and so on). Addiction psychiatry also deals with subjects in dual diagnosis, i.e. individuals with addiction issues along with co-occurring psychiatric disorders. However, despite its well established “dignity” to be part of psychiatry, most mental health's professionals believe that it is not a primarily psychiatric field due to the frequent co-occurrence of internistic/medical issues. In addition, the situation of psychiatric training specifically addressed to addiction is widely diversified across the European countries. Therefore, most psychiatrists do not possess specific qualifications and formation on this increasing field of psychiatry. The present lecture aims at providing an insight into the issues related to the diatribe between psychiatry and medicine on addiction medicine/psychiatry, specifically focusing on differences across European countries.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
7
|
Vecchiotti R, Meschini L, Borsella I, Pianella U, Orsolini L, Panichi M, Valchera A. The metacognitive functioning in bipolar patients and in bipolar alcoholics patients. Eur Psychiatry 2016. [DOI: 10.1016/j.eurpsy.2016.01.175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
IntroductionMetacognition is described as the set of human abilities that allows us to recognize and think about own and other people's mental states. We use these skills in order to overcome psychological and interpersonal issues and to cope emotional, cognitive and behavioral suffering. Studies that focusing on metacognition in bipolar disorder (BD) are still limited and data are controversial. Our purpose is investigating the difference between BD patients and BD patients with alcohol addiction (BD + A), in terms of metacognitive functions. In addition, we want to assess among BD + A whether the increase in metacognitive functions mediates the relationship between symptoms at T0 and T1.MethodsForty patients were recruited for this study. A set of tests was performed on each patient to formulate a metacognitive and clinical evaluation. A single measurement was performed on 20 BD patients. Two measurements (T0–T1) were carried out on the 20 BD + A patients, after an integrated treatment.ResultsData shown significant differences between these two groups. As regards the treatment of BD + A patients, differences were found between T0 and T1. Among the BD + A patients, reduction in the Beck Cognitive Insight Scale (BCIS-SC, P 0. 042) scores between T0 and T1, leads to the prediction of symptom improvement.ConclusionsOur results confirm the existence of a specific profile of metacognitive functioning in these patients. Our results reveal that the metacognitive functions appear to be predictors of the improvement in the remission of symptoms.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
8
|
Orsolini L, Valchera A, Vecchiotti R, Panichi M, De Berardis D. Psychosis and polydrug abuse in a patient with Dandy-Walker variant. Eur Psychiatry 2016. [DOI: 10.1016/j.eurpsy.2016.01.1061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Abstract
Background and purposeDandy Walker “syndrome” (DWS) was firstly defined by Dandy and Blackfan, and then described by Hart et al. [1] as a series of neurodevelopmental anomalies in the posterior fossa, including Dandy-Walker (DW) malformation, DW variant (cerebellar hypoplasia/aplasia of the cerebellar vermis and cystic dilatation of the fourth ventricle), mega-cisterna magna and posterior fossa arachnoid cyst. Mental symptoms have been associated with DWS in previous reports, but the spectrum of mental symptomatology widely varies between clinical cases, ranging from psychotic/schizophrenia-like to mood/cognitive symptoms [2].MethodsHere we describe a case of psychosis and polydrug abuse in a 27-year-old man with DW variant a 4-year history of polydrug abuse, sporadic alcohol abuse, epilepsy and psychotic symptoms including delusions of reference/persecution, suspiciousness, associated with obsessive thoughts, mood lability and persistent anxiety.ResultsHe was recovered for a 28-day program of detoxification from drug addiction/stabilization of psychiatric symptoms. Family history of Bipolar Disorder, gambling disorder (father) and depression (mother). The mental status examination at baseline revealed slowness of thought, psychomotor retardation, aboulia/anhedonia/apathy/hypomimic facies/asthenia/social withdrawal/deflected mood/poor thought content/blunted affect/self-neglect/poor insight, cognitive impairment and oppositive and partially collaborative attitude and behaviour. Borderline intelligence activity was found on WAIS-R (IQ = 79). At the baseline, he was taking carbamazepine 400 mg BID (baseline serum level: 6.720 μg/ml), gabapentin (400 mg BID), paroxetine (20 mg/d), olanzapine (10 mg/d) and methadone (70 ml/d), with a poor response/control both on psychotic and seeking drug symptomatology.References not available.ConclusionsFurther DWS clinical cases should be evaluated in order to better investigate the role of this variant to addictive and psychotic symptoms.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Collapse
|
9
|
De Berardis D, Conti C, Iasevoli F, Valchera A, Fornaro M, Cavuto M, Brucchi M, Perna G, Pompili M, Modabbernia A, Lucidi G, Mazza M, Martinotti G, Di Giannantonio M. Alexithymia and its relationships with acute phase proteins and cytokine release: an updated review. J BIOL REG HOMEOS AG 2014; 28:795-799. [PMID: 25620189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The alexithymia construct is multidimensional and comprises several features: (a) difficulty in identifying and describing feelings, (b) difficulty in distinguishing feelings from the bodily sensations, (c) diminution of fantasy, and (d) concrete and poorly introspective thinking. Altered immune responses have been seen in some psychiatric disorders and several data suggest that analogous changes could also be observable in alexithymia. Hence, the aim of this review is to investigate the relationships between alexithymia and acute phase proteins and cytokines in psychiatric, psychosomatic and medical diseases. Several studies have reported an association between alexithymia and higher circulating levels of acute phase proteins, especially C-Reactive Protein. Moreover, in alexithymic subjects the pro-inflammatory and anti-inflammatory cytokine balance may be tuned toward a pro-inflammatory imbalance with a concomitant altered cell-mediated immunity. These findings may be consistent with the "stress-alexithymia hypothesis". Therefore, the screening of alexithymic traits and the administration of appropriate psychological and psychotherapeutical interventions should be integral parts of disease management programs. Supplying such interventions will probably help with prevention of the development of the disease and/or its exacerbation by improving the quality of life of alexithymic individuals.
Collapse
Affiliation(s)
- D De Berardis
- Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital G. Mazzini, ASL 4 Teramo, Italy
| | - C Conti
- Department of Neurosciences and Imaging, University G. DAnnunzio, Chieti, Italy
| | - F Iasevoli
- Laboratory of Molecular Psychiatry and Psychopharmacotherapeutics, Section of Psychiatry, Department
| | - A Valchera
- Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, Ascoli Piceno, Italy
| | - M Fornaro
- Department of Scienze della Formazione, University of Catania, Italy
| | | | - M Brucchi
- National Health Service, U. O. S. D. Senology, Hospital G. Mazzini, ASL 4, Teramo, Italy
| | - G Perna
- Hermanas Hospitalarias, FoRiPsi, Department of Clinical Neurosciences, Villa San Benedetto Menni, Albese con Cassano, Como, Italy
| | - M Pompili
- Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, SantAndrea Hospital, Sapienza University of Rome, Italy
| | - A Modabbernia
- Department of Psychiatry and Psychiatry Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
| | - G Lucidi
- Director, School of Nursing, MeSvA Department, University of LAquila, Italy
| | - M Mazza
- Department of Life, Health and Environmental Sciences, University of LAquila, Italy
| | - G Martinotti
- Department of Neurosciences and Imaging, University G. DAnnunzio, Chieti, Italy
| | - M Di Giannantonio
- Department of Neurosciences and Imaging, University G. DAnnunzio, Chieti, Italy
| |
Collapse
|
10
|
De Berardis D, Conti CM, Marini S, Ferri F, Iasevoli F, Valchera A, Fornaro M, Cavuto M, Srinivasan V, Perna G, Carano A, Piersanti M, Martinotti G, Di Giannantonio M. Is there a role for agomelatine in the treatment of anxiety disorders?A review of published data. Int J Immunopathol Pharmacol 2013; 26:299-304. [PMID: 23755745 DOI: 10.1177/039463201302600203] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Anxiety disorders (Ads) are the most common type of psychiatric disorders, Pharmacologic options studied for treating ADs may include benzodiazepines, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRIs), noradrenergic and specific serotonergic antidepressants (NaSSA) and serotonin and noradrenaline reuptake inhibitors (SNRIs). Agomelatine, a new melatonergic antidepressant, has been shown effective in various types of mood disorders. Moreover, some evidence points towards a possible efficacy of such a drug in the treatment of ADs. Therefore, the aim of this review was to elucidate current (facts and views) data on the role of agomelatine in the treatment of ADs. The trials evaluating agomelatine in the treatment of generalized anxiety disorder are few but, overall, encouraging in regards to its efficacy. However, further randomized, placebo-controlled studies on larger samples use are needed. Apart from some interesting case reports, no large studies are, to date, present in literature regarding agomelatine in the treatment of other ADs, such as panic disorder, social anxiety disorder, obsessive-compulsive disorder and post-traumatic stress disorder. Therefore, the clinical efficacy and the relative good tolerability of agomelatine in generalized anxiety (GAD) warrants further investigation in ADs.
Collapse
Affiliation(s)
- D De Berardis
- Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital G. Mazzini, ASL 4 Teramo, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
De Berardis D, Conti CM, Campanella D, Carano A, Di Giuseppe B, Valchera A, Tancredi L, Serroni N, Pizzorno AM, Fulcheri M, Gambi F, Sepede G, Moschetta FS, Salerno RM, Ferro FM. Evaluation of plasma antioxidant levels during different phases of illness in adult patients with bipolar disorder. J BIOL REG HOMEOS AG 2008; 22:195-200. [PMID: 18842173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
The aim of the present study is to evaluate role of plasma antioxidants (albumin, bilirubin and uric acid) in patients suffering from type I Bipolar Disorder (BD-I) during different phases of illness: acute mania, euthymia and bipolar depression. Medical records of consecutive 110 BD-I patients (38 patients with acute mania, 35 in euthymic state, full remission, and 37 in depressive phase) were reviewed to evaluate plasma antioxidant levels. Laboratory data of 40 healthy controls were also obtained. The scores of Young Mania Rating Scale (YMRS), Bech-Rafaelsen Manic Rating Scale (BRMRS) and Hamilton Rating Scale for Depression (HAM-D) were evaluated. Serum uric acid levels were higher in acute mania than other patient subgroups and healthy controls. Serum uric acid levels directly correlated with BRMRS and YMRS scores. No differences were found between clinical groups during different phases and healthy controls concerning albumin and bilirubin. In conclusion, the results of the present study support the notion that serum uric acid levels may be higher in patients with BP-I (especially during manic phases) which may suggest a dysregulation of the purinergic system. However, limitations should be considered and further studies are needed.
Collapse
Affiliation(s)
- D De Berardis
- Department of Oncology and Neurosciences, Institute of Psychiatry, G. d'Annunzio University, Chieti, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
De Berardis D, Conti C, Campanella D, Carano A, Scali M, Valchera A, Serroni N, Pizzorno A, D'Albenzio A, Fulcheri M, Gambi F, Larovere R, Cotellessa C, Salerno R, Ferro F. Evaluation of C-Reactive Protein and Total Serum Cholesterol in Adult Patients with Bipolar Disorder. Int J Immunopathol Pharmacol 2008; 21:319-24. [DOI: 10.1177/039463200802100208] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
The aim of the present study is to evaluate the role of CRP and Total Cholesterol (TC) in patients suffering from type I Bipolar Disorder (BD-I). Moreover, the goal is to elucidate possible CRP and TC differences in different phases of BD-I: acute mania, euthymia and bipolar depression. Medical records of 90 BD-I patients (30 patients with acute mania, 30 in euthymic state, full remission, and 30 in depressive phase) were reviewed to evaluate serum CRP and TC levels. Laboratory data of 30 healthy controls were also obtained. The scores of Young Mania Rating Scale (YMRS), Bech-Rafaelsen Manic Rating Scale (BRMRS) and Hamilton Rating Scale for Depression (HAM-D) were evaluated. CRP levels were higher in acute mania and depressive phase subgroups when compared to healthy controls. CRP was positively associated with BRMRS and YMRS scores in acute mania and with HAM-D in depressive phase subgroups. TC levels were lower in all clinical groups compared to controls. TC levels were negatively correlated to BRMRS, YMRS and HAM-D. In conclusion, the results of the present study support the notion that CRP and TC may be altered in patients with BP-I.
Collapse
Affiliation(s)
- D. De Berardis
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. d'Annunzio” of Chieti, Ascoli Piceno, Italy
- Department of Mental Health, ASL Teramo, Ascoli Piceno, Italy
| | - C.M. Conti
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. d'Annunzio” of Chieti, Ascoli Piceno, Italy
- Department of Psychology, University “G. d'Annunzio” of Chieti, Ascoli Piceno, Italy
| | - D. Campanella
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. d'Annunzio” of Chieti, Ascoli Piceno, Italy
- Department of Mental Health, ASL Teramo, Ascoli Piceno, Italy
| | - A. Carano
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. d'Annunzio” of Chieti, Ascoli Piceno, Italy
- Department of Mental Health, ASUR Marche 8, Civitanova Marche, Ascoli Piceno, Italy
| | - M. Scali
- Department of Mental Health, ASUR Marche 8, Civitanova Marche, Ascoli Piceno, Italy
| | - A. Valchera
- Casa di Cura “San Giuseppe”, Ascoli Piceno, Italy
| | - N. Serroni
- Department of Mental Health, ASL Teramo, Ascoli Piceno, Italy
| | - A.M. Pizzorno
- Department of Mental Health, ASL Teramo, Ascoli Piceno, Italy
| | - A. D'Albenzio
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. d'Annunzio” of Chieti, Ascoli Piceno, Italy
| | - M. Fulcheri
- Department of Psychology, University “G. d'Annunzio” of Chieti, Ascoli Piceno, Italy
| | - F. Gambi
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. d'Annunzio” of Chieti, Ascoli Piceno, Italy
| | - R. Larovere
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. d'Annunzio” of Chieti, Ascoli Piceno, Italy
| | - C. Cotellessa
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. d'Annunzio” of Chieti, Ascoli Piceno, Italy
| | - R.M. Salerno
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. d'Annunzio” of Chieti, Ascoli Piceno, Italy
| | - F.M. Ferro
- Department of Oncology and Neurosciences, Institute of Psychiatry, University “G. d'Annunzio” of Chieti, Ascoli Piceno, Italy
| |
Collapse
|
13
|
Bersani G, Arcangeli T, Venturi P, Valchera A, Taddei I. Auditory event related potentials and obsessive compulsive symptoms. Eur Psychiatry 1998. [DOI: 10.1016/s0924-9338(99)80292-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
14
|
Röder HU, Valchera A, Heinsohn C, Schmidt B. [Radiotherapy of esophageal carcinoma: an assessment of patients treated at Tübingen from 1977 to 1982]. Strahlenther Onkol 1989; 165:1-10. [PMID: 2916169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
We report on the results of therapy of 116 patients with esophagus carcinoma. The patients have been attended to at the Medical Radiation Institute of Tübingen between 1977 and 1982. In 95 cases sole radiation was performed as operation was impossible. The other patients underwent a combined surgical-radiotherapeutical treatment. The joint doses of radiation applied ran from 50 to 70 Gy in five to seven weeks' time. In particular we considered the total survival rate according to tumor stage, the local tumor control and the period until relapse. 22% of the primarily irradiated patients achieved complete remission, 42% reached particular remission and 15% achieved minimal tumor remission (total response rate: 79%). Merely in 8% of the cases the tumor did not respond perceptibly. In the other cases irradiation had to be interrupted because of general worsening, or the patients got lost to post-therapeutical observation. The total survival rates, all stages taken into account, arose as follows: one year: 36.8%, two years: 12.6%, five years: 7.3%. After sole radiotherapy in 67% of the cases which had a radiologically verified relapse more than six months passed by before a local recurrence tumor was stated. The bad prognosis of the esophagus carcinoma, as demonstrated in literature, is entirely confirmed-the negative selection of our patients taken into account. The high rank of radiotherapy in achieving effective palliation is emphasized.
Collapse
Affiliation(s)
- H U Röder
- Radiologische Klinik, Universität Tübingen
| | | | | | | |
Collapse
|